The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD, Gary Oderda, PharmD, MPH, Joseph Biskupiak, PhD, MBA, Douglas S. Burgoyne, PharmD, FAMCP, Steven G. Avey, RPh, MS, FAMCP, Steven R. Feldman, MD, PhD
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
Urothelial carcinoma (also known as transitional-cell carcinoma) is the most common subtype of bladder cancer, accounting for more than 90% of bladder cancer diagnoses in the United States. In 2016, nearly 77,000 cases of bladder cancer are expected to be diagnosed in the United States, and more than 16,000 people will die from this disease. The incidence of bladder cancer increases with age, with a median age of 73 years at diagnosis.
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - Online First, Value in Oncology
In her presidential address, Julie M. Vose, MD, MBA, Chief of the Oncology/Hematology Division, University of Nebraska Medical Center, Omaha, highlighted the importance of multimodal care and its effect on the quality of care and enhancement of clinical trial participation among patients with cancer.
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - Emerging Therapies, Online First
Serial vaccination with galinpepimut-S induces immunologic responses in patients with acute myeloid leukemia (AML) who are in remission. Disease-free survival (DFS) and overall survival (OS) improved in patients with AML who had an immune response to galinpepimut-S, according to data from a phase 2 trial of galinpepimut-S that were presented at ASCO 2016.
Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease
On March 30, 2016, the FDA approved defibrotide sodium (Defitelio; Jazz Pharmaceuticals) for hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction after hematopoietic stem-cell transplant. This is the first drug approved for severe hepatic VOD. “The approval of Defitelio fills a significant need in the transplantation community to treat this rare but frequently fatal complication,” said Richard Pazdur, MD.
“I’m guessing that, like me, most of our readers have not heard the term ‘hassle map,’” says Dr Nash in this editorial. He reviews a recent white paper titled, “The Marketplace Revolution: Shattering the Foundation of the $3 Trillion Sick-Care Marketplace,” authored by Tom Main and Adrian Slywotzky.
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
Lung cancer is one of the most frequently diagnosed cancers, and is the leading cause of cancer-related mortality worldwide and in the United States among men and women. Non–small-cell lung cancer (NSCLC) is the most common form of the disease, accounting for approximately 85% of all lung cancer cases.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19